Jeg liker sammenfallet av god newsflow og et chart som antyder bunnformasjon.
4 Likes
Bra driv her da. Nærmer seg 50 øringen 
2 Likes
Ser Bull ut for første gang siden 2013
Mot ATH nå 
5 Likes
Neste target 60 øringen 
Stengte på 2,055 
7 Likes
Arg, når du er en dag for seint ute og ikke løper etter. Hadde tenkt å kjøpe på 1,6x, men når den var på 1,7 så droppet jeg det. Ser pent ut nå. Har gigantpotensiale, så oppsiden er stor med den lille mcap de har i dag.
2 Likes
Hvis den plutselig ramler ned i bucketen “snabbgrabbarnas svensk bull medtech”, så kan den gå veldig veldig langt.
Milliardprising nesten en selvfølge hvis den forutsetningen faller på plass.
Men, kan godt komme en sell the news i morgen, og det må jo komme oppfinansieringer.
4 Likes
Derfor jeg tenkte å kjøpe den, en milliard kan da ikke være umulig? Hater dog å kjøpe 20% over det jeg planla…
Vi får nå se om dette bare er den vanlige pump og dumpen som vi har sett x ganger før i denne aksjen ifbm news slipp i morgen.
Nei, så fort stiger den ikke. Den har klatret 25-30% mot kapital dag i morgen, stiger muligens litt da men forventer litt tilbake etter det.
Absolutt! 
men dro en linje i ukeschart før i dag etter at jeg så chartet ditt og da så ikke brudd på nedtrenden like overbevisende ut:
Så kom jeg hjem fra sykkeltur og så den meget hyggelige avslutningen i dag og da ser det jo bedre ut 
Blir det volum skal den vel opp og teste 2,50?
6 Likes
Results from European multicentre study with follow-up of 80 Episealer® patients accepted for publication in Knee Surgery, Sports Traumatology, Arthroscopy (KSSTA)
TUE, SEP 15, 2020 07:40 CET
Episurf Medical (Nasdaq: EPIS B) today announces that a manuscript with the title “Patient specific metal implants for focal chondral and osteochondral lesions in the knee – Excellent clinical results at 2 years” from a European multicentre study with 24 months’ follow-up of 80 Episealer® Knee implant patients has been accepted for publication in the scientific journal Knee Surgery, Sports Traumatology, Arthroscopy (KSSTA). The publication is expected to be available online shortly.
The study reports on the clinical outcomes for 80 patients from 9 clinics in 6 European countries, that have undergone treatment with the individualised Episealer® Knee implant for treatment of isolated focal chondral and osteochondral defects in the knee. The author group, led by Dr. med. Johannes Holz, Park-Klinik Manhagen, OrthoCentrum, Hamburg, Germany, consists of some of the most experienced Episealer® users and most knowledgeable European knee specialists, and they have followed-up their Episealer® patients and pooled their prospectively collected results.
“For us users and Episurf Medical, it is a milestone and great pleasure that our clinical data, as part of our multicentre study, impressively demonstrates the extremely successful and safe application of a new and innovative treatment concept - the Episealer® implant. We would like to take this opportunity to thank all our highly motivated colleagues and the engineers and employees of Episurf Medical for their consistent cooperation and support. We are convinced that the Episealer® implant is a fixture in the treatment of patients who are on a path towards osteoarthritis”, says Dr. med. Johannes Holz.
The authors of the publication have evaluated the clinical outcomes for the patient group using the patient reported outcome measures scoring systems KOOS (Knee injury and Osteoarthritis Outcome Score) and VAS (Visual Analogue Scale). In KOOS all measured subdomains including Pain, Symptoms, Function in daily living, Function in sports and recreation as well as Quality of life, showed significant improvements. Also, the improvement in VAS score exceeded the minimal important difference, and all results remained over time. The authors of the publication conclude that the Episealer® implants provide significant clinical and functional improvement. They also find that the study indicates that there is a definitive place for the Episealer® in the management of cartilage defects in the knee joint.
“It is important with all new devices and innovative treatments that they are properly evaluated. This study provides very important information detailing the results in 80 patients at 2 years minimum follow up. The impact and effectiveness of the Episealer ® implant is impressive and I am proud to be part of this study” says Ass. Prof. Tim Spalding, University Hospitals Coventry and Warwickshire NHS Trust, UK, and co-author of the publication.
“It is particularly agreeable that previously reported clinical data in a smaller cohort and with limited number of surgeons, are upheld in this study from a number of surgeons and a number of European markets. The study is among the largest ever reported on these kinds of patients and emphasises the universal character of both problem and solution” says Prof. Leif Ryd, Senior medical advisor, Episurf Medical.
5 Likes
Haha, kurs 2,35. Hadde tenkt å kjøpe på 1,6x, kursen gikk til 1,7x og jeg tenkte, whatever, får bare fortsette å fiske litt. Skulle visst bare løpt etter 
Det var da kjekt å se en hadde rett den var kjøp i sommer, skulle bare hatt aksjene ennå 
Undervurderte kapital dagen ja, den ga noe voldsomt med prosenter.
Men det er jo ikke kapitaldagen som er driveren, det er de kliniske resultatene. 
2 Likes
Mitt råd er at det en aksje du vurderer å kjøpe, så bare kjøp litt med en gang i tilfelle den stikker. Det gjør jeg hele tiden.
2 Likes
Tok motvillig 25% av bordet her, 47% opp på noen dager.
2 Likes
Ei krone siden Mars
I kjent Funcom stil så skriker jeg bare HODL!
2 Likes